Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Expert Rev Proteomics. 2023 Jul-Dec;20(7-9):143-150. doi: 10.1080/14789450.2023.2255752. Epub 2023 Sep 13.
Clinical proteomics studies of Alzheimer's disease (AD) research aim to identify biomarkers useful for clinical research, diagnostics, and improve our understanding of the pathological processes involved in the disease. The rapidly increasing performance of proteomics technologies is likely to have great impact on AD research.
We review recent proteomics approaches that have advanced the field of clinical AD research. Specifically, we discuss the application of targeted mass spectrometry (MS), labeling-based and label-free MS-based as well as affinity-based proteomics to AD biomarker development, underpinning their importance with the latest impactful clinical studies. We evaluate how proteomics technologies have been adapted to meet current challenges. Finally, we discuss the limitations and potential of proteomics techniques and whether their scope might extend beyond current research-based applications.
To date, proteomics technologies in the AD field have been largely limited to AD biomarker discovery. The recent development of the first successful disease-modifying treatments of AD will further increase the need for blood biomarkers for early, accurate diagnosis, and CSF biomarkers that reflect specific pathological processes. Proteomics has the potential to meet these requirements and to progress into clinical routine practice, provided that current limitations are overcome.
阿尔茨海默病（AD）的临床蛋白质组学研究旨在确定对临床研究、诊断有用的生物标志物，并加深对疾病相关病理过程的理解。蛋白质组学技术性能的快速提高可能会对 AD 研究产生重大影响。
我们回顾了最近推进临床 AD 研究领域的蛋白质组学方法。具体来说，我们讨论了靶向质谱（MS）、基于标记和无标记 MS 以及基于亲和性的蛋白质组学在 AD 生物标志物开发中的应用，并用最新的有影响力的临床研究支持它们的重要性。我们评估了蛋白质组学技术如何适应当前的挑战。最后，我们讨论了蛋白质组学技术的局限性和潜力，以及它们的范围是否可能超出当前基于研究的应用。
迄今为止，AD 领域的蛋白质组学技术在很大程度上仅限于 AD 生物标志物的发现。最近首次成功开发出治疗 AD 的疾病修饰疗法将进一步增加对早期、准确诊断的血液生物标志物以及反映特定病理过程的 CSF 生物标志物的需求。如果能够克服当前的局限性，蛋白质组学有可能满足这些需求并进入临床常规实践。
